Skip to main content

VBI Vaccines, Inc. (VBIV)

NASDAQ: VBIV · IEX Real-Time Price · USD
2.78
-0.08 (-2.80%)
At close: Nov 26, 2021 1:00 PM
2.89
0.11 (3.96%)
After-hours:Nov 26, 2021 4:58 PM EST
Market Cap715.31M
Revenue (ttm)714,000
Net Income (ttm)-66.33M
Shares Out257.30M
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,162,159
Open2.98
Previous Close2.86
Day's Range2.74 - 2.91
52-Week Range2.44 - 4.83
Beta1.93
AnalystsStrong Buy
Price Target8.00 (+187.8%)
Earnings DateNov 8, 2021

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP progr...

IndustryBiotechnology
Employees127
Stock ExchangeNASDAQ
Ticker SymbolVBIV
Full Company Profile

Financial Performance

In 2020, VBI Vaccines's revenue was $1.06 million, a decrease of -52.23% compared to the previous year's $2.22 million. Losses were -$46.23 million, -15.66% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for VBI Vaccines stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 187.77% from the latest price.

Price Target
$8.00
(187.77% upside)
Analyst Consensus: Strong Buy

News

VBI Vaccines to Participate in Jefferies London Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

1 week ago - Business Wire

VBI Vaccines, Inc. (VBIV) Reports Q3 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 25.00% and -58.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

2 weeks ago - Business Wire

VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting®...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

3 weeks ago - Business Wire

Analysts Estimate VBI Vaccines, Inc. (VBIV) to Report a Decline in Earnings: What to Look Out for

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI's Prophylactic 3-Antigen H...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

VBI Vaccines to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Ag...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

7 Penny Stocks Waiting on The FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPl...

2 months ago - InvestorPlace

Best Penny Stocks to Buy in September 2021? 3 to Watch Right Now

Which penny stocks are on your watchlist this month? The post Best Penny Stocks to Buy in September 2021?

Other symbols:RIGSENS
2 months ago - PennyStocks

VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 12.50% and -73.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported...

3 months ago - Business Wire

Earnings Preview: VBI Vaccines, Inc. (VBIV) Q2 Earnings Expected to Decline

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

VBI Vaccines Appoints Linda Bain to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

4 months ago - Business Wire

VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported...

4 months ago - Business Wire

Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday

Investors almost seemed ready to take profits once shares hit their highest level since February.

4 months ago - The Motley Fool

VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial

VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine candidate VBI-2902a. VBI-2902a was well-...

4 months ago - Benzinga

9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again

These penny stocks are showing high bullish sentiment right now; are they on your watchlist? The post 9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again appeared first on Penny Stocks to Buy, ...

4 months ago - PennyStocks

VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced...

4 months ago - Business Wire

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Pa...

DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), today announced final results from a Phase 1b/2a study on BRII-179...

5 months ago - Business Wire

VBI Vaccines to Present at Upcoming Scientific Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

5 months ago - Business Wire

VBI Vaccines (VBIV) is in Overbought Territory: What's Next?

VBI Vaccines (VBIV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

5 months ago - Zacks Investment Research

VBI Vaccines Announces Results of Annual General Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of dise...

5 months ago - Business Wire

VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

5 months ago - Zacks Investment Research

VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

5 months ago - Business Wire